Full Tentative Programme (13-15 November)
Day 1, 13 November 2019
Welcome & Opening of Symposium
8:30 – 8:45 Welcome Address, Shigeki
Sugii, Simon Cool, Co-Chairs of Organizing Committee
Introduction to the Singapore Cell Therapy
Manufacturing Programmes
8:45 – 8:55 Allogeneic
Stem Cell Manufacturing (ASTEM)
Simon Cool, Institute
of Medical Biology, A*STAR
8:55 – 9:05 Integrated Manufacturing
Programme for Autologous Cell Therapy (IMPACT)
John Connolly, Institute
of Molecular and Cell Biology, A*STAR
9:05 – 9:15 Critical Analytics for Manufacturing
of Personalized-Medicine Programme (CAMP)
Krystyn van Vliet, MIT and Singapore-MIT
Alliance for Research & Technology
9:15 – 10:00 KEYNOTE LECTURE (Chair: Steve Oh, BTI,
Singapore)
Genetically engineered immunity for cancer: the
development and global regulatory approvals of chimeric antigen receptor (CAR)
T cells and what’s coming next
Bruce Levine, University
of Pennsylvania, USA
Session 1. Stem Cell Therapy
Chair: Simon Cool, Institute of Medical Biology,
Singapore
10:00-10:20 Long term
clinical outcomes of stem cell therapy in cartilage repair: Are we ready for
the next step?
Francis KL Wong,
Duke-NUS-Medical School, Singapore
10:20
– 10:50 MORNING TEA BREAK
Session 1 cont. Stem Cell Therapy
10:50 – 11:10 Establishing the National Cell Therapy
Program for process development and clinical manufacturing of cell & gene
therapy products in Singapore
Lip Kun Tan, National University
Hospital, Singapore
11:10 – 11:30 Stem cell expansion of cord blood graft” vs
“bridging support with 3rd party hematopoietic stem/progenitor cells
Satoshi Takahashi, University
of Tokyo, Japan
11:30 – 11:45 Short talk: The Influence of
the amniotic fluid stem cell secretome on
cardiomyocyte cellular behaviour
Marek Kukumberg, National
University of Singapore
11:45 – 12:00 Short
talk: Long-term culture of human pancreatic progenitors: an alternative source
of insulin-secreting beta cells
Jamie Trott, Institute of Medical Biology,
Singapore
12:00 – 12:20 Cardiovascular progenitors for heart regeneration in preclinical
models
Lynn Yap, Duke-NUS
Medical School, Singapore
12:20 – 12:35 Short
talk: Generation of induced motor neurons (iMNs) from
human fibroblasts for cell therapy in spinal cord injury model
Hyunah Lee, Ulsan National Institute
of Science and Technology, Korea
12:35 – 12:55 Softer,
faster, better! – Substrate mechanics drives superior somatic cell
reprogramming outcomes
Justin Cooper-White, Australian Institute for Bioengineering and Nanotechnology, Australia
12:55
– 14:15 LUNCH BREAK
Session 2. Manufacturing and Quality Control
Co-Chairs:
Anthony Davies, Dark House Consulting, USA
Shin Kawamata, Foundation for Biomedical Research &
Innovation, Japan
14:15 – 14:35 Effective
& cost-effective, but unaffordable? The future of cell and gene therapy
Anthony Davies, Darkhouse Consulting, US
14:35 – 14:55 Bringing
immune cell therapies to patients, innovative solutions for CAR T
manufacturing, enabling scalability and cost reduction
Ohad Karnieli, ATVIO, Israel
Drew
Titmarsh, Scaled Biolabs, USA
15:15 – 15:35 Future of transfusion medicine – Human induced pluripotent
stem cells derived blood?
Jaichandran Sivalingam, Bioprocessing Technology Institute, Singapore
Tong Ming Liu, Institute of
Molecular and Cell Biology, Singapore
15:50
– 16:10 Nature
inspired DMSO-, protein-, serum-free and chemically defined biopreservation
solution, new horizon of precision in cell manufacturing and processing
Mark Kline, X-Therma, USA
16:10
– 16:40 AFTERNOON TEA BREAK
16:40 – 17:00 In process
monitoring for mass production of pluripotent stem cells
Shin Kawamata, Foundation for Biomedical Research
& Innovation, Japan
17:00 – 17:20 Automated cell
expansion: Trends & outlook of critical technologies
May-Win
Naing, Singapore Institute of Manufacturing Technology, Singapore
17:20 – 17:40 Regeneus’ novel allogeneic stem cell
platform for Osteoarthritis
Charlotte Morgan, Regeneus, Australia
17:40 – 17:55 Short
talk: Sub-confluent culture of human mesenchymal stem cells on biodegradable
polycaprolactone microcarriers enhances bone healing of rat calvarial
defect
Alan Tin-Lun Lam, Bioprocessing Technology Institute, Singapore
17:55 – 18:40 Panel discussion
Panellists: C Morgan,
MW Naing, O Karnelli, M Kline, D Titmarsh
Moderators: A. Davies and S. Kawamata
END OF DAY 1
Day 2, 14 November 2019
Session
3. Business of Cell & Gene Therapy
Chair:
Steve Oh, Bioprocessing
Technology Institute, Singapore
08:30-08:50 Developing
allogeneic cellular immunotherapies with iPSC technology
Wen Bo Wang, Fate Therapeutics, USA
08:50-09:10 Radically
simplifying scale-up and clinical translation of hMSCs
and extracellular vesicles
Mayasari Lim, RoosterBio Inc, USA
09:10-09:25 Short talk: Characterization and application
of size-dependent mesenchymal stem cell subpopulations separated using
label-free microfluidics
Yin
Lu, Singapore-MIT Alliance in Research and Technology, Singapore
Arthur
Sampaio, STEMCELL Technologies, Canada
`
09:45-10:05 Development
of an injectable cartilage gel using chondrogenic progenitor cells
Bryan Choi, ATEMs, Korea
10:05-10:35 MORNING TEA BREAK
10:35-10:55 Commercialization of advanced allogeneic cell
therapy product in Korea and beyond
Antonio Lee, Medipost, Korea
10:55-11:15 Continuous bioprocessing platform for CAR T
Xiangliang Lin, Esco
Aster, Singapore
11:15-11:35 The patient in the incubator: the cytocentric approach to avoiding suboptimal transients
Alicia Henn, Biospherix
Ltd, USA
11:35-11:55 Pooled mesenchymal stromal cells – a
potential break through therapy for critical limb ischemia (CLI) Management
Pawan
Gupta, Stempeutics, India
11:55-12:35 Panel discussion
Panellists: B Levine, M Lim,
A Sampaio, B Choi, XL Lin, A Henn, P Gupta
Moderators: WB Wang & T
Lee
12:35-14:00 LUNCH BREAK
Session
4. Responsible Pathways to Translation with Cell Therapies
Chair:
Tamra Lysaght, National
University of Singapore
14:00-14:05 Introduction
Tamra Lysaght, National University of
Singapore, Singapore
14:05-14:25 The
use of professional disciplinary systems to regulate innovation: lessons from
stem cell practice in Australia
Cameron Stewart, University of Sydney,
Australia
14:25-14:45 The oversight of clinical innovation in a
medical marketplace
Wendy Lipworth, University of Sydney,
Australia
14:45-15:05 Expedited
regulatory pathways for stem cell-based products in Malaysia: ethical and legal
considerations
Mohammad
Firdaus Bin Abdul Aziz, University of Malaya, Malaysia
15:05-15:20 Short Talk: Autologous cell treatments: who owns the cells?
Patrick
Foong, Western Sydney University, Australia
15:20-15:40 Regulatory
updates on cell and gene therapy products in Singapore
Lee Lee Ong, Health
Sciences Authority, Singapore
15:40-16:10 AFTERNOON TEA BREAK (hosted by BIOSPHERIX)
16:10-16:30 Making the unproven proven
Mickey Koh, St George’s Hospital, UK
16:30-17:20 Panel discussion
Panellists:
C Stewart, W Lipworth, F Aziz, P Foong, LL Ong, M Koh
Moderator: T Lysaght
17:20-18:05 KEYNOTE LECTURE (Chair: Ray Dunn, IMB,
Singapore)
The evolution and challenges introducing
cell-based therapies into burn care and scar therapy
Fiona Wood, Royal Perth
Hospital, Australia
18:05-20:00 POSTER SESSION WITH
WINE & CHEESE
END OF THE DAY 2
Day 3, 15 November 2019
Session
5. Immuno & Gene Therapy
Chair:
John Connolly, Institute of Molecular and Cell
Biology, Singapore
09:00-09:25 Virus specific T cells as
platform for solid tumor immunotherapy
John
Connolly, Institute of Molecular and Cell Biology, Singapore
09:25-09:40 Short talk: FOXP3 gene editing towards
autologous stem cell therapy to cure IPEX Syndrome
Esmond Lee, Stanford
University, USA
09:40-10:05 Gamma Delta T cells for anti-cancer
immunotherapy
Shu Wang, National University of Singapore,
Singapore
10:05-10:35 MORNING
TEA BREAK
10:35-11:00 T cell therapy as a localized modulator of
tumor immune environment
Antonio Bertoletti, Duke-NUS Medical School, Singapore
11:00-11:15 Short talk: Characterisation of novel human
genomic safe harbours for transgene expression
Matias Autio, Genome
Institute of Singapore, Singapore
11:15-11:40 Expansion of human tumor infiltrating γδ T cells for cancer therapy
Michael Lotze, University of Pittsburgh, USA
11:40-13:15 LUNCH BREAK
Session
6. Advanced Technologies
Chair:
Karl Tryggvason, Duke-NUS Medical School, Singapore
13:15-13:35 The Science of stem cell therapy – parameters
affecting dosing and efficacy
Andre van Wijnen, Mayo Clinic, USA
13:35-13:50 Short
talk: Metformin affects pancreatic differentiation from human embryonic stem
cells
Adrian Kee Keong Teo, Institute of
Molecular and Cell Biology, Singapore
13:50-14:10 Cellular
therapy for burns/skin injuries: Laminin-based epidermal keratinocytes culture
system in xeno-free and chemically defined condition
Monica Tjin, Duke-NUS Medical School,
Singapore
14:10-14:30 Minimizing immunogenicity of iPS cells by
custom disruption of HLA genes utilizing CRISPR-Cas9 genome editing: Towards 2nd
generation iPS cell stock for cost-effective cell therapy
Akitsu
Hotta, Kyoto University, Japan
14:30-15:00 AFTERNOON TEA BREAK
15:00-15:20 Manufacturing cell therapies with predictive
therapeutic outcomes: Case studies in critical quality attributes for stem
& stromal cell therapies
Krystyn
J. Van Vliet, MIT and Singapore-MIT Alliance for
Research & Technology
15:20-15:40 Astrocytes derived from spinal muscular
atrophy (SMA) patients are hyper-reactive and exacerbate neuronal degeneration
Lawrence
Stanton, Qatar Biomedical Research Institute, Qatar
15:40-16:00 Endothelial instability predisposes ischemic
stroke patients to recurrent vascular events
Christine Cheung, Nanyang Technological University, Singapore
16:00-16:15 Short talk: Retina specific laminins model inter-photoreceptor matrix to
drive differentiation of photoreceptors from human pluripotent stem cells
Hwee Goon Tay, Duke-NUS Medical
School, Singapore
16:15-16:45 DR SUSAN LIM AWARD FOR OUTSTANDING YOUNG
INVESTIGATOR 2019 LECTURE (Introduction: Ray Dunn, President SCSS)
Global translation in early embryos and embryonic stem cells depends on
the essential transcription factor PRDM10
Daniel Messerschmidt, Institute of Molecular and
Cell Biology, Singapore
16:45-17:00 AWARDS, CLOSING REMARKS & FAREWELL
END
OF DAY 3 & END OF SYMPOSIUM
Organized by:
